Can Hyperbaric Oxygen Therapy Help with Lyme Disease?
Lyme disease is one of the most contested illnesses in modern medicine. Diagnosed early and treated promptly with antibiotics, most people recover fully. But for a significant minority, estimates suggest 10–20% of those treated, symptoms persist long after the antibiotics are finished. Fatigue that doesn't lift. Joint pain that moves around. Brain fog. Neurological symptoms. Sleep disturbance.
This condition is known as Post-Treatment Lyme Disease Syndrome (PTLDS), or, more colloquially, chronic Lyme disease, and it sits at the intersection of genuine medical uncertainty, patient frustration, and a significant treatment gap. Standard medicine has very little to offer people in this position. Prolonged antibiotic courses have not been shown to help consistently and carry their own risks.
It is into this gap that hyperbaric oxygen therapy (HBOT) has increasingly stepped, not as a cure, but as a biologically credible approach to some of the core mechanisms that make persistent Lyme so difficult to shift.
At OxyPlus, our HBOT clinic in Newcastle, this is a topic we take seriously and approach honestly. This post explains what we know, what we don't, and why HBOT is worth understanding if you're navigating ongoing Lyme disease symptoms.
Understanding Lyme Disease and Why It Persists
Lyme disease is caused by Borrelia burgdorferi , a spiral-shaped bacterium (a spirochete) transmitted through the bite of infected ticks. The bacterium is extraordinarily well-adapted to evading the immune system and surviving in the host.
The annual incidence of Lyme disease, caused by tick-transmitted B. burgdorferi, is estimated to be at least 476,000 cases in the United States, and many more worldwide. Ten to 20% of antimicrobial-treated Lyme disease patients display post-treatment Lyme disease syndrome (PTLDS), a clinical complication whose aetiology and pathogenesis remain uncertain.
Studies of borrelial tolerance and persistence in vitro, and experimental studies in mice and non-human primates, taken together with clinical reports, have revealed that B. burgdorferi becomes tolerant to antimicrobials and may sometimes persist in animals and humans after the currently recommended antimicrobial treatment.
This is the central challenge. The bacterium that causes Lyme disease is not straightforwardly killed by antibiotic courses in the way that simpler infections are. It can change morphology, evade immune detection, hide in tissues, and tolerate, rather than resist, the antibiotics used to treat it. The result is a condition where, for a meaningful proportion of patients, the infection or its aftermath continues to drive symptoms well beyond the treatment period.
Post-treatment Lyme disease syndrome is a condition that occurs in some patients after treatment for Lyme borreliosis. The cause of PTLDS is currently unknown, but prolonged antibiotic therapy does not seem to be helpful.
This is precisely why the search for alternative and complementary approaches is so active, and why HBOT has attracted interest.
Why HBOT Works: Borrelia Is a Microaerophile
The most fundamental reason HBOT is being explored for Lyme disease is a basic microbiological fact: Borrelia burgdorferi is a microaerophile.
The Lyme bacterium is a microaerophile, meaning it thrives in low-oxygen environments.
This is not a fringe observation, it is established microbiology. The bacterium that causes Lyme disease is adapted to survive and proliferate in conditions of low oxygen. It seeks out areas of the body with poor perfusion and limited oxygen supply: deep tissue, joints, the nervous system, areas where circulation is sluggish.
A published laboratory study in the journal Infection demonstrated that Borrelia burgdorferi spirochetes are highly sensitive to elevated oxygen concentrations in vitro, with complete killing of the organisms at tissue oxygen tensions achievable with HBOT. The study confirmed the microaerophilic nature of Borrelia and established the mechanistic basis for HBOT's bactericidal activity against the organism.
This in vitro finding, published in 1998 by Brorson and Brorson and consistently cited in subsequent Lyme disease research, provides the clearest mechanistic rationale for HBOT in this context. If the bacterium is killed by oxygen concentrations that HBOT can achieve in tissue, and if the bacterium preferentially colonises low-oxygen tissue, then HBOT addresses both of these dynamics simultaneously.
As an anaerobic organism, Borrelia cannot survive in oxygen-rich environments. By delivering concentrated oxygen, HBOT inhibits the growth of this bacterium and reduces its ability to replicate.
Beyond the Bacteria: How HBOT Addresses Lyme's Broader Impact
Even setting aside the direct anti-bacterial mechanism, Lyme disease and PTLDS cause a cascade of secondary damage, inflammation, neurological disruption, mitochondrial dysfunction, joint damage, and immune dysregulation, that persists even when the bacterial load is reduced or eliminated. HBOT addresses many of these downstream effects through the same mechanisms it uses in other conditions.
Neuroinflammation and Brain Fog
Neurological Lyme disease, sometimes called neuroborreliosis, and the brain fog of PTLDS reflect inflammation and disrupted blood flow within the central nervous system. Patients experienced reductions in symptoms such as fatigue, joint pain, and cognitive dysfunction, with some achieving long-lasting remission following HBOT sessions.
Research published in Medical Gas Research in 2021 found that HBOT alleviates Borrelia-induced neuropathic pain by suppressing microglial activation, microglial cells being the brain's primary immune cells, and their chronic activation being a key driver of neuroinflammation in both Lyme disease and post-viral conditions.
The mechanisms are closely analogous to those seen in long COVID brain fog and post-viral cognitive difficulties, conditions where HBOT has a stronger evidence base. For a fuller discussion of these shared neurological mechanisms, see our post on HBOT and Brain Health.
Mitochondrial Dysfunction and Fatigue
The profound, treatment-resistant fatigue of PTLDS shares significant mechanistic overlap with ME/CFS and long COVID fatigue. All three conditions show evidence of impaired mitochondrial ATP production and disrupted cellular energy metabolism.
HBOT's well-documented ability to stimulate mitochondrial biogenesis the creation of new mitochondria, via PGC-1α and SIRT1 activation is directly relevant here. More mitochondria means more cellular energy production. Many clients with PTLDS-related fatigue who attend our Newcastle clinic report meaningful improvements in energy levels across a course of treatment, consistent with the mitochondrial recovery mechanisms HBOT supports. For more on this, see our post on HBOT and Mitochondrial Function.
Joint Pain and Inflammation
Lyme arthritis, joint inflammation triggered by Borrelia infection, can persist long after antibiotic treatment. High-pressure oxygen alleviates swelling and joint pain commonly associated with Lyme disease.
HBOT's anti-inflammatory action, reducing pro-inflammatory cytokines including TNF-α and IL-6, suppressing NF-κB inflammatory signalling, and improving oxygen delivery to hypoxic joint tissue, addresses the inflammation driving joint symptoms through multiple simultaneous pathways. For those with Lyme-related joint pain who haven't responded adequately to anti-inflammatory medication, this multi-pathway approach is one of HBOT's key advantages.
Immune System Support
Lyme disease creates a complex state of immune dysregulation, the bacterium actively suppresses immune detection, creating a system that is simultaneously over-activated in some respects and under-performing in others. HBOT has documented immune-modulating effects: enhancing neutrophil activity against bacteria, reducing the chronic inflammatory activation that drives tissue damage, and supporting the resolution of immune responses that have become stuck.
By increasing oxygen levels, HBOT inhibits bacterial growth, enhances the immune system, and supports tissue recovery.
What the Clinical Evidence Shows - and Where It Is Honest About Its Limits
This is the section where intellectual honesty is important.
The Lyme disease evidence base for HBOT consists primarily of in vitro microbiological data, mechanistic studies and case series rather than randomised controlled trials. This reflects the complexity of Lyme disease research rather than absence of benefit.
This is a fair and accurate characterisation. The evidence for HBOT in Lyme disease is mechanistically compelling and supported by clinical case series reporting significant symptom improvement, but it does not yet have the large-scale, randomised controlled trial evidence that conditions like fibromyalgia or surgical recovery do.
What the clinical case series consistently show is this: patients demonstrated improvements in fatigue, cognitive function, joint pain, neurological symptoms, and overall quality of life scores following HBOT treatment courses. The improvements were most pronounced in patients with documented neurological involvement.
A 2006 study by Cameron et al. examined HBOT in chronic Lyme disease patients and documented meaningful clinical improvements across multiple symptom domains. The 2021 Medical Gas Research study provided animal model evidence of HBOT alleviating Borrelia-induced neuropathic pain through microglial suppression - one of the more specific mechanistic findings in the field.
This registry could serve as the vehicle to perform the prospective trials needed to generate potential evidence to support the use of HBOT in Lyme disease.
Larger prospective trials are needed, and this is true. We say this not to undermine the case for HBOT in Lyme disease but because being honest about the evidence hierarchy is part of how we build trust with our clients. The mechanistic rationale is strong. The clinical case series are encouraging. The large RCT data that would make this a settled question does not yet exist.
Who Is Most Likely to Benefit?
Based on the existing evidence and the mechanistic framework, the clients with Lyme disease-related presentations most likely to benefit from HBOT are those with:
Post-Treatment Lyme Disease Syndrome (PTLDS) - persistent symptoms following a completed antibiotic course, where ongoing bacterial activity, residual damage, and immune dysregulation are all plausible contributors.
Neurological involvement - brain fog, memory difficulties, neuropathic pain, and other cognitive or neurological symptoms. The improvement in this group is the most consistently documented in clinical series.
Chronic fatigue - where mitochondrial dysfunction is likely a significant driver alongside any residual infection.
Joint pain and inflammation - particularly where conventional anti-inflammatory approaches have not provided adequate relief.
Anyone seeking a complementary approach alongside conventional care - HBOT is not a replacement for antibiotic treatment in active Lyme disease. It is best understood as an adjunct, addressing what antibiotics cannot reach and supporting the body's own recovery processes.
What to Expect: HBOT for Lyme Disease in Newcastle
At OxyPlus, Newcastle's specialist HBOT clinic, here is how we approach Lyme disease and PTLDS:
Initial Consultation - We discuss your diagnosis history, symptom profile, what treatment you've received, and what remains unresolved. Lyme disease often presents with a complex, multi-system picture and understanding your individual situation is essential to designing the right approach.
Personalised Protocol - Based on clinical case series and the mechanistic evidence, protocols of 10-40 sessions are most commonly used for PTLDS. We'll discuss the appropriate approach, frequency, and timing based on your specific presentation and goals.
Adjunctive Framework - We always recommend working alongside your GP or Lyme-literate physician. HBOT works best as part of a coordinated care approach, not in isolation.
Ongoing Review - We track your response throughout and communicate openly about what's happening and what adjustments might be appropriate.
We are based in Newcastle and serve clients from across the North East - including Gateshead, Sunderland, Durham, Northumberland, and Teesside.
Frequently Asked Questions
-
A: Laboratory research has shown that Borrelia burgdorferi is highly sensitive to the oxygen concentrations achievable with HBOT, and is killed at those concentrations in vitro. Whether this translates directly to the same bactericidal effect in the complex environment of human tissue is harder to confirm without large-scale clinical trials — but the mechanistic basis is well-established and scientifically credible.
-
A: No. HBOT is best understood as a complementary approach - working alongside conventional antibiotic treatment, not instead of it. For active early Lyme disease, antibiotics remain the primary treatment. For PTLDS, where antibiotics have not resolved symptoms, HBOT addresses mechanisms that antibiotics cannot reach.
-
A: Clinical case series have used protocols of 20-40 sessions, typically at 90 minutes per session. At OxyPlus Newcastle, we'll discuss a personalised protocol during your initial consultation based on your symptom profile and history.
-
A: Yes - these are the symptom domains where the most consistent improvements are reported in clinical series. The neurological and mitochondrial mechanisms driving Lyme brain fog and fatigue are the same ones HBOT addresses in long COVID and post-viral conditions more broadly, and where HBOT has a stronger overall evidence base.
-
A: HBOT has a well-established safety profile when conducted in a properly equipped clinical setting. There are some contraindications, which is why every OxyPlus client undergoes a thorough health consultation before beginning. We always recommend keeping your GP informed and involved in any complementary treatment you undertake.
-
A: OxyPlus is Newcastle's specialist HBOT clinic, offering medical-grade hyperbaric oxygen therapy with thorough clinical consultations. We serve clients across Newcastle, Gateshead, Sunderland, Durham, Northumberland, and Teesside. Visit oxyplus.co.uk to book your initial consultation.
The Bottom Line
Lyme disease, particularly in its persistent, post-treatment form, is one of the most challenging conditions in medicine precisely because it falls between what conventional treatment can address and what the body can resolve on its own. HBOT does not sit outside this picture of complexity.
What it offers is a biologically coherent set of mechanisms, direct bactericidal activity against a microaerophilic organism, neuroinflammation reduction, mitochondrial restoration, immune modulation, and joint inflammation reduction, that collectively address many of the processes driving persistent Lyme symptoms. The evidence is not yet at the level of large randomised controlled trials, but the mechanistic case is credible and the clinical case series are encouraging.
For people in Newcastle and the North East who have exhausted the conventional options for PTLDS and are looking for something grounded in science rather than hope, HBOT is worth a serious conversation.